1 December 2022 - To 27 November 2022, the TGA has received 709 reports which have been assessed as likely to ...
17 November 2022 - To 13 November 2022, the TGA has received 706 reports which have been assessed as likely to ...
3 November 2022 - To 30 October 2022, the TGA has received 704 reports which have been assessed as likely to ...
11 November 2022 - AbbVie announced today the EMA's CHMP has adopted an opinion following a nine month review of the ...
28 October 2022 - EMA’s safety committee (PRAC) has recommended measures to minimise the risk of serious side effects associated ...
20 October 2022 - To 16 October 2022, the TGA has received 705 reports which have been assessed as likely to ...
6 October 2022 - To 2 October 2022, the TGA has received 703 reports which have been assessed as likely to ...
23 September 2022 - To 18 September 2022, the TGA has received 712 reports which have been assessed as likely to ...
14 September 2022 - The TGA has published an independent expert report examining the incidence of serious injury and death ...
8 September 2022 - To 4 September 2022, the TGA has received 699 reports which have been assessed as likely to ...
25 August 2022 - To 21 August 2022, the TGA has received 674 reports which have been assessed as likely to ...
11 August 2022 - To 7 August 2022, the TGA has received 665 reports which have been assessed as likely to ...
29 July 2022 - To 24 July 2022, the TGA has received 615 reports which have been assessed as likely to ...
22 July 2022 - EMA’s human medicines committee, CHMP, has recommended that Rubraca (rucaparib camsylate) should no longer be used ...
14 July 2022 - To 10 July 2022, the TGA has received 609 reports which have been assessed as likely to ...